The targeting of the immunosuppressive TME cytokines IL-10, VEGF or TGF-ß may effectively reinstate robust anti-tumor immunity by preventing IgG1 to IgG4 class switching and promoting anti-tumor B cell subsets to engage in tumor rejection. This evidence concerns the gene VEGFA and neoplasm.